Literature DB >> 17207713

DQB1*0301 and DQB1*0601 modulate narcolepsy susceptibility in Koreans.

Seung-Chul Hong1, Ling Lin, Betty Lo, Jong-Hyun Jeong, Yoon-Kyung Shin, Su-Yeon Kim, Yongsil Kweon, Jing Zhang, Mali Einen, Anajane Smith, John Hansen, F Carl Grumet, Emmanuel Mignot.   

Abstract

The association of narcolepsy with HLA-DQB1*0602 is established in Japanese, African-Americans, European, and North American Caucasians. We examined DRB1, DRB3, DRB4, DRB5, DQA1, and DQB1 in 163 patients with centrally mediated daytime sleepiness (100 with narcolepsy) and 211 Korean controls. In this population, the DQB1*0602 association was always evident in the context of the DRB1*1501-DQA1*0102-DQB1*0602 haplotype. The DQB1*0602 association was highest in cases with hypocretin deficiency (100% vs 13% in controls), most of which had narcolepsy-cataplexy (81%). A weaker DQB1*0602 (45%) association was present in cases without cataplexy. No human leukocyte antigen (HLA) association was present in idiopathic hypersomnia or in cases with normal cerebrospinal fluid (CSF) hypocretin-1. As in other populations, DQB1*0602 homozygosity increased risk in cases with cataplexy and/or hypocretin deficiency (odds ratio = 2.0 vs heterozygotes). Non-DQB1*0602 allelic effects were also observed but could not be interpreted in the context of DQB1*0602 overabundance and linkage disequilibrium. We therefore next analyzed compound heterozygote effects in 77 subjects with either hypocretin deficiency or cataplexy and one copy of DRB1*1501-DQA1*0102-DQB1*0602, a sample constructed to maximize etiologic homogeneity. In this analysis, we found additional predisposing effects of DQB1*0301 and protective effects for DQA1*0103-DQB1*0601. Unexpectedly, the predisposing effects of DQB1*0301 were present in the context of various DQA1-bearing haplotypes. A predisposing effect of DQA1*0303 was also suggested. These results indicate a remarkable consistency in the complex HLA association present in narcolepsy across multiple ethnic groups.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17207713     DOI: 10.1016/j.humimm.2006.10.006

Source DB:  PubMed          Journal:  Hum Immunol        ISSN: 0198-8859            Impact factor:   2.850


  22 in total

1.  Presentations of primary hypersomnia in Chinese children.

Authors:  Fang Han; Ling Lin; Jing Li; Adi Aran; Song X Dong; Pei An; Long Zhao; Ming Li; Qian Y Li; Han Yan; Jie S Wang; Hui Y Gao; Mei Li; Zhan C Gao; Kingman P Strohl; Emmanuel Mignot
Journal:  Sleep       Date:  2011-05-01       Impact factor: 5.849

2.  DQB1 locus alone explains most of the risk and protection in narcolepsy with cataplexy in Europe.

Authors:  Mehdi Tafti; Hyun Hor; Yves Dauvilliers; Gert J Lammers; Sebastiaan Overeem; Geert Mayer; Sirous Javidi; Alex Iranzo; Joan Santamaria; Rosa Peraita-Adrados; José L Vicario; Isabelle Arnulf; Giuseppe Plazzi; Sophie Bayard; Francesca Poli; Fabio Pizza; Peter Geisler; Aleksandra Wierzbicka; Claudio L Bassetti; Johannes Mathis; Michel Lecendreux; Claire E H M Donjacour; Astrid van der Heide; Raphaël Heinzer; José Haba-Rubio; Eva Feketeova; Birgit Högl; Birgit Frauscher; Antonio Benetó; Ramin Khatami; Francesca Cañellas; Corinne Pfister; Sabine Scholz; Michel Billiard; Christian R Baumann; Guadalupe Ercilla; Willem Verduijn; Frans H J Claas; Valérie Dubois; Jacek Nowak; Hans-Peter Eberhard; Sylvain Pradervand; Charlotte N Hor; Manuela Testi; Jean-Marie Tiercy; Zoltán Kutalik
Journal:  Sleep       Date:  2014-01-01       Impact factor: 5.849

3.  HLA dosage effect in narcolepsy with cataplexy.

Authors:  Astrid van der Heide; Willem Verduijn; Geert W Haasnoot; Jos J M Drabbels; Gert J Lammers; Frans H J Claas
Journal:  Immunogenetics       Date:  2014-10-03       Impact factor: 2.846

Review 4.  Genetics of sleep and sleep disorders.

Authors:  Amita Sehgal; Emmanuel Mignot
Journal:  Cell       Date:  2011-07-22       Impact factor: 41.582

5.  HLA-DPB1 and HLA class I confer risk of and protection from narcolepsy.

Authors:  Hanna M Ollila; Jean-Marie Ravel; Fang Han; Juliette Faraco; Ling Lin; Xiuwen Zheng; Giuseppe Plazzi; Yves Dauvilliers; Fabio Pizza; Seung-Chul Hong; Poul Jennum; Stine Knudsen; Birgitte R Kornum; Xiao Song Dong; Han Yan; Heeseung Hong; Cristin Coquillard; Joshua Mahlios; Otto Jolanki; Mali Einen; Isabelle Arnulf; Sophie Lavault; Birgit Högl; Birgit Frauscher; Catherine Crowe; Markku Partinen; Yu Shu Huang; Patrice Bourgin; Outi Vaarala; Alex Désautels; Jacques Montplaisir; Steven J Mack; Michael Mindrinos; Marcelo Fernandez-Vina; Emmanuel Mignot
Journal:  Am J Hum Genet       Date:  2015-01-08       Impact factor: 11.025

6.  HLA-DQ allele competition in narcolepsy: a comment on Tafti et al. DQB1 locus alone explains most of the risk and protection in narcolepsy with cataplexy in Europe.

Authors:  Hanna M Ollila; Marcelo Fernandez-Vina; Emmanuel Mignot
Journal:  Sleep       Date:  2015-01-01       Impact factor: 5.849

7.  Correlates to Problem Behaviors in Pediatric Narcolepsy: A Pilot Study.

Authors:  Althea Robinson Shelton; Beth Malow
Journal:  J Clin Sleep Med       Date:  2017-12-15       Impact factor: 4.062

8.  HLA DQB1*06:02 negative narcolepsy with hypocretin/orexin deficiency.

Authors:  Fang Han; Ling Lin; Barbara Schormair; Fabio Pizza; Giuseppe Plazzi; Hanna M Ollila; Sona Nevsimalova; Poul Jennum; Stine Knudsen; Juliane Winkelmann; Cristin Coquillard; Farbod Babrzadeh; Tim M Strom; Chunlin Wang; Michael Mindrinos; Marcelo Fernandez Vina; Emmanuel Mignot
Journal:  Sleep       Date:  2014-10-01       Impact factor: 5.849

Review 9.  Genetic and immunologic aspects of sleep and sleep disorders.

Authors:  James M Parish
Journal:  Chest       Date:  2013-05       Impact factor: 9.410

10.  HLA-DQB1*06:02 allele frequency and clinic-polysomnographic features in Saudi Arabian patients with narcolepsy.

Authors:  Saad M Al Shareef; Eiman AlAnbay; Mujahed A AlKhathlan; Zahid Shakoor; Mustafa Alnasser; Khalid D Hamam; Adel S Alharbi; Aljohara S Almeneessier; Ahmed S BaHammam
Journal:  Sleep Breath       Date:  2018-09-05       Impact factor: 2.816

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.